In a study presented at the ACG 2019 meeting, investigators discuss their groundbreaking work on inflammatory bowel disease.
The TARGET-IBD study was 1 of the lynchpin studies presented during the American College of Gastroenterology’s Annual Scientific Meeting (ACG 2019).
In the study, investigators estimated the prevalence of any use of mesalamine among patients with Crohn’s disease before and after the implementation of the guideline.
The investigators found little difference between academic and community practice in implementation of the new standards.
In an interview at ACG with MD Magazine Julie Mallory-Crawford, MD, senior director of Scientific & Medical Affairs for TARGET PharmaSolutions,
MD Magazine: What is the methodology behind the TARGET-IBD study?
Mallory-Crawford: TARGET-IBD has a really unique position in that it is able to gather what is going on in real world clinical practice.
So, we have both community and academic sites and we're able to capture the medications being used. It’s really an interesting take on outcomes side effects and really what's happening in the real-world treatment of disease of IBD.
MD Magazine: What is the real-world impact of the TARGET-IBD study?
Mallory-Crawford: I think the real-world impact is really just this this chance to capture data on patients that aren't normally captured in in clinical trials. So patients who maybe are at extremes of disease, extremes of age, maybe in community practices that aren't normally a part of research.
So really this idea of being able to capture patients in a very unique way and capturing the real-world impact of therapies on patients with ulcerative colitis and Crohn's.